image: Alto SoftBank's second Vision Fund has led a new funding round for San Francisco-based drug delivery startup Alto Pharmacy, according to a Reuters report . Reuters says the new round totaled $250 million and valued Alto Pharmacy (formerly known as ScriptDash) at more than $1 billion. Other existing investors such as Jackson Square Ventures and Greenoaks Capital also participated in the new funding, according to Reuters . The investment comes at a stormy time for SoftBank, which has seen some of its portfolio companies struggle and recourse to job cuts to stay stable. The most notable of that cohort is WeWork, which pulled out of a planned initial public offering last year and needed a $9.5 billion bailout from SoftBank to stay afloat. Alto is among a cohort of tech startups challenging traditional pharmacy chains by taking the drug delivery process online. The company was founded in 2015 as ScriptDash and rebranded itself as Alto in 2017 after a $23 million inv
A very big new acquisition has happened in the tech industry, with Okta (NASDAQ: OKTA), the publicly-traded cloud identity and access management software provider, announcing an agreement to buy Auth0, a fellow cloud identity software provider, for a price of $6.5 billion to be paid all with shares. A $6.5 billion exit for Auth0 marks a major win for the startup scene in Seattle, the tech hub where Auth0 is based and also a major win for the company's backers and investors. Auth0 last raised venture funding last year in July with a $120 million Series F round that valued the company at $1.9 billion. Now, it's about to sell for more than triple that amount. Auth0 has raised more than $330 million in total venture funding, with investors including the likes of Salesforce Ventures, Bessemer Venture Partners, Telstra Ventures, Sapphire Ventures, and DTCP. Salesforce Ventures led Auth0's most recent $120 million Series F round. With its acquisition of a fellow cloud identity a